跳至主要内容

MedPath Trial Home

机构资讯 AI 研究

数据来源：ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

搜索试验。追踪管线。洞察审批。由 AI 驱动的临床研究情报平台。

产品

临床试验
药物情报
全球审批
深度研究
价格方案

资源

常见问题
搜索

公司

资讯
关于我们
联系我们

法律

隐私政策
服务条款

免责声明： 本网站提供信息检索和数据分析服务。内容不构成医疗建议。适应性评估仅供参考，不能替代合格医疗专业人员的咨询。数据来源于公共注册库和监管机构；MedPath 不保证数据的完整性或准确性。请以原始资料为准。

© 2026 MedPath Trial 版权所有

服务条款隐私政策

我们重视您的隐私

我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。

Bioprojet Pharma

首页临床试验发起方与机构Bioprojet Pharma

Bioprojet Pharma

Unknown Belgian address, Unknown, 比利时

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

相关临床试验

29

14 进行中

药物批准

20

批准总数

监管机构

3

监管机构数

成立时间

N/A

概览

试验阶段分布

阶段

试验数

占比

1 期

25

86.2%

2 期

2

6.9%

3 期

1

3.5%

试验状态分布

进行中（未招募）

14

48.3%

已完成

6

20.7%

招募中

8

27.6%

撤回

1

3.5%

相关临床试验

该机构主办的试验（29）

Open label, single-center, two-part pharmacokinetic study:Part I: Relative bioavailability study to compare the pharmacokinetics of BP1.4979 after administration of single oral doses of BP1.4979 as sustained release formulation and actual immediate release formulation, under fasting and fed conditions, in healthy subjects.Part II: Pharmacokinetics of BP1.4979 after a 14-day dosing period with b.i.d. administration of BP1.4979 as sustained release formulation in healthy subjects.

May 202432 名受试者

A multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 2 trial to evaluate the efficacy and safety of BP1.7881 in adult patients with eosinophilic esophagitis.

进行中（未招募）

Mar 202424 名受试者

Exploratory study to assess the pharmacokinetic interaction of doxepin with adrenaline after a concomitant co-administration using the Anapen® device and to compare the adrenaline comparative bioavailability with Anapen®500 commercial form in healthy normal weight male subjects

Nov 202320 名受试者

1206d849eb8f9b8b

Aug 202384 名受试者

A double-blind, placebo-controlled pilot trial of BP1.4979 for the treatment of binge eating disorder.

进行中（未招募）

Aug 202386 名受试者

Open label, single-center, cross-over randomized, relative bioavailability study comparing 4 new BF2.649 (pitolisant) tablet formulations versus the reference pitolisant (Wakix®) tablet formulation after single oral administrations in healthy male subjects.

进行中（未招募）

Jul 202316 名受试者

An Exploratory, Multicenter, Randomized, double-blind, placebo-controlled study evaluating the effect and safety of pitolisant in children and adolescents with Autism Spectrum Disorders.

May 202366 名受试者

Randomized, double-blind, placebo-controlled study assessing the safety, tolerability, pharmacokinetics and pharmacodynamics of pitolisant after repeated oral ascending doses for 14 days, including the pitolisant effect on cardiac repolarization in healthy volunteers.

进行中（未招募）

Apr 202375 名受试者

第 1 页，共 4 页

药物批准

按机构分类的批准

NMPA

National Medical Products Administration

5

药物批准

EMA

European Medicines Agency

4

药物批准

CIMA_AEMPS

Spanish Agency for Medicines and Medical Devices

11

药物批准

近期批准

TIORFAN INFANTIL 4 MG/ML SUSPENSIÓN ORAL

Pitolisant Hydrochloride Tablets

Pitolisant Hydrochloride Tablets

OZAWADE 4,5 MG COMPRIMIDOS RECUBIERTOS CON PELICULA

OZAWADE 18 MG COMPRIMIDOS RECUBIERTOS CON PELICULA

AMGLIDIA 0,6 mg/ml SUSPENSION ORAL

AMGLIDIA 6 mg/ml SUSPENSION ORAL

Racecadotril Powder

资讯

暂无资讯文章

本页目录

概览
相关临床试验29
药物批准20
资讯

返回机构列表